How India Exports Volini to the World

As of March 2026, "Volini" has not been approved by the U.S. Food and Drug Administration (FDA) for marketing in the United States. A search of the FDA's Orange Book reveals no approved Abbreviated New Drug Applications (ANDAs) or New Drug Applications (NDAs) for this product. Consequently, "Volini" is not listed as a reference listed drug (RLD) in the U.S. This absence indicates that the product has not undergone the FDA's rigorous review process to establish its safety and efficacy for the U.S. market.

Given that "Volini" is not FDA-approved, its importation into the U.S. is subject to strict regulatory scrutiny. The FDA enforces import alerts to prevent the entry of unapproved drugs, which could apply to "Volini" if attempted to be imported without proper authorization. The lack of FDA approval and potential import restrictions may explain why, despite 116 active Indian exporters and 1,406 shipment records, the U.S. is not among the top five destination countries for "Volini."

In the European Union (EU) and the United Kingdom (UK), medicinal products require marketing authorization from the European Medicines Agency (EMA) or the UK's Medicines and Healthcare products Regulatory Agency (MHRA) before they can be marketed. As of March 2026, "Volini" does not hold a marketing authorization from either the EMA or the MHRA. This absence indicates that "Volini" has not been evaluated for compliance with EU or UK regulatory standards, including Good Manufacturing Practice (GMP) requirements.

The lack of marketing authorization in these regions suggests that "Volini" is not legally available in the EU or UK markets. This regulatory status may influence the product's export patterns, as evidenced by the fact that France is the only EU country among the top five destinations, accounting for 25.7% of exports.

The World Health Organization (WHO) maintains the Model List of Essential Medicines, which identifies medications considered essential for basic healthcare systems. As of the latest edition, "Volini" is not included in this list. Additionally, "Volini" has not undergone the WHO Prequalification Programme, which assesses the quality, safety, and efficacy of medicinal products.

Regarding pharmacopoeial standards, "Volini" is not monographed in the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), or Indian Pharmacopoeia (IP). This absence indicates that there are no official compendial standards for "Volini" in these major pharmacopoeias, which may impact its acceptance in markets that rely on these standards.

In India, "Volini" is classified as an over-the-counter (OTC) product, allowing it to be sold without a prescription. The Central Drugs Standard Control Organization (CDSCO) does not list "Volini" under Schedules H, H1, or X, which are categories for prescription-only medications.

The National Pharmaceutical Pricing Authority (NPPA) oversees drug pricing in India. As of March 2026, "Volini" is not subject to price control under the Drug Price Control Order (DPCO), indicating that its pricing is determined by market forces.

For exports, the Directorate General of Foreign Trade (DGFT) requires a No Objection Certificate (NOC) for certain pharmaceutical products. However, as an OTC product, "Volini" may not require an export NOC, facilitating its international distribution.

A search of the Indian Patent Office and international patent databases indicates that "Volini" is not protected by active patents as of March 2026. This status allows multiple manufacturers to produce and export the product, contributing to the presence of 116 active Indian exporters. The absence of patent protection also means that "Volini" faces generic competition in various markets.

In June 2025, the NPPA announced a revision of the ceiling prices for several non-scheduled drugs, leading to a 5% increase in the maximum retail price of certain OTC products. Although "Volini" is not under price control, this adjustment may influence market dynamics and pricing strategies.

In September 2025, the CDSCO issued new guidelines for the export of pharmaceutical products, emphasizing the need for stringent quality checks and compliance with Good Manufacturing Practices (GMP). These guidelines aim to enhance the credibility of Indian pharmaceutical exports and may impact the export processes for products like "Volini."

In December 2025, the WHO updated its Model List of Essential Medicines, adding several new medications but not including "Volini." This exclusion indicates that "Volini" is not considered essential for basic healthcare systems by the WHO, which may affect its adoption in certain markets.

In February 2026, the EMA introduced a new electronic product information (ePI) implementation guide to standardize the submission of product information. While "Volini" does not have EMA approval, this development highlights the increasing emphasis on digitalization in regulatory processes.

In March 2026, the DGFT reported a 10% increase in pharmaceutical exports from India compared to the previous year. This growth reflects the expanding global reach of Indian pharmaceutical products, including "Volini," which has been exported to 54 countries with a total export value of $2.9 million USD.

These developments underscore the dynamic nature of the pharmaceutical regulatory landscape and the importance of staying informed to navigate the complexities of international markets.

India's pharmaceutical industry, including the production of topical analgesics like Volini, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 70% of India's API requirements are fulfilled by Chinese suppliers. This dependency exposes the supply chain to significant risks, as any disruption in Chinese manufacturing or export activities can lead to shortages and increased costs for Indian pharmaceutical products.

The COVID-19 pandemic underscored these vulnerabilities when Chinese factory shutdowns caused immediate scarcities of essential APIs, leading to price surges and supply chain disruptions. Despite efforts to bolster domestic production through initiatives like the Production Linked Incentive (PLI) scheme, which aims to reduce import dependence by half, India's pharmaceutical sector remains susceptible to external supply shocks due to its continued reliance on Chinese KSMs and APIs.

Our proprietary trade data from 2022 to 2026 reveals that Sun Pharmaceutical Industries Limited dominates Volini exports, accounting for 72.2% of the total export value. The top five exporters collectively represent 92.7% of the market share, indicating a high supplier concentration. Such dependency on a limited number of suppliers heightens the risk of supply chain disruptions if any of these key players face operational challenges.

The Indian government's PLI scheme, launched in October 2024, aims to reduce import dependence on critical pharmaceutical ingredients by incentivizing domestic production. While this initiative is a positive step toward diversifying the supplier base, its impact on reducing single-source risks for products like Volini will depend on the successful establishment and scaling of new manufacturing facilities.

Recent geopolitical tensions have significantly impacted global shipping routes critical to pharmaceutical supply chains. In February 2026, the closure of the Strait of Hormuz disrupted the movement of oil and other essential goods, leading to increased transportation costs and delays. Similarly, instability in the Red Sea has forced shipping companies to reroute vessels, adding time and expense to deliveries. These disruptions have cascading effects on the availability and pricing of pharmaceutical products, including Volini, as supply chains are strained and costs escalate.

Additionally, ongoing U.S.-China trade tensions have introduced uncertainties in the supply of APIs and KSMs. The U.S. Food and Drug Administration (FDA) has highlighted the risks associated with dependence on foreign suppliers and the potential for supply chain disruptions due to geopolitical factors. Such geopolitical dynamics necessitate proactive risk management strategies to ensure the continuity of pharmaceutical supplies.

• Diversify Supplier Base: Engage with multiple API and KSM suppliers across different regions to reduce dependency on a single source, thereby enhancing supply chain resilience.

• Invest in Domestic Manufacturing: Leverage government incentives like the PLI scheme to establish and expand domestic production facilities for critical pharmaceutical ingredients, decreasing reliance on imports.

• Enhance Supply Chain Visibility: Implement advanced tracking and monitoring systems to gain real-time insights into supply chain operations, enabling prompt responses to potential disruptions.

• Develop Contingency Plans: Establish comprehensive risk management protocols, including alternative shipping routes and emergency stockpiles, to mitigate the impact of geopolitical and logistical disruptions.

• Strengthen Regulatory Compliance: Ensure adherence to international quality standards and regulatory requirements to maintain market access and consumer trust, particularly in the face of evolving global trade policies.

RISK_LEVEL: HIGH